Fundraising FoxMPM BioImpact — 2019 Investments
5 investments dated 2019 · listed companies and verified rows first · show all
Co-investorsVersant VenturesVivo Capital
ElevateBio is a contract development and manufacturing organization (CDMO) for advanced therapies, offering discovery, process development, analytics, manufacturing, and regulatory support for cell therapies, viral vectors, mRNA therapeutics, and gene editing.
BiotechDeep TechHealthtechWaltham, US
David Hallal(CEO)inMike Paglia(Chief Technology Officer)Ger Brophy(CEO)in
Co-investorsEcoR1 CapitalSamsara BioCapitalSoftBank Vision Fund
Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies.
BiotechDigital HealthMedical DevicesWaltham, US
Amanda Wagner(CEO)inDan Matloff(Executive Officer)Jiaping Gu(Director)Jeffrey Goldberg(Executive Officer, Director)
BoardLaura Brass(Director)inKai Wucherpfennig(Director)
Co-investorsAgent CapitalDC Investment PartnersLifelinkLongwood FundM VenturesMedical Excellence Capital+5 more
SiO2 Materials Science develops precision molded polymer containers with thin glass-like barrier coatings for pharmaceutical and biopharmaceutical applications.
BiotechMedical DevicesNew MaterialsAuburn, US
Robert S. Abrams(Executive Officer, Director)inRobert Pangborn(Director)John Belfance(Director)Jean-Marie Painvin(Director)Thomas Strungmann(Director)Jared Morris(Director)
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.